Microsatellite Instability in Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 26
Special Issue Editors
Interests: microsatellite unstability; metabolism; ICI resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Although immune checkpoint inhibitor (ICI) therapy is currently the standard of care in microsatellite-unstable (MSI) metastatic colorectal cancer (CRC), ICI therapy, alone or in combination with other therapies, is not a treatment approach in microsatellite-stable (MSS) CRC, which is present in 95% of patients. In addition, for unknown reasons, there is higher efficacy with ICI in limited disease than in metastatic MSI disease. Therefore, understanding biological differences between located and metastatic MSI would be critical to improve results in metastatic disease. Finally, treatment duration, monotherapy vs. dual therapy, and radiological evaluation, especially in limited MSI disease, are clinical questions that are not resolved.
While much of the focus of ICI resistance has so far been on tumor mutational burden and immune signatures, metabolism and how it influences ICI efficacy have been less explored. This Special Issue will highlight the role of metabolism in cancer cells and the microenvironment, covering both basic and clinical aspects that advance our understanding of targeting MSI tumors.
Dr. Joan Maurel
Dr. Vicente Alonso-Orduña
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- microsatellite instability
- colorectal cancer
- immune checkpoint inhibitors
- immune signatures
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
